Company Overview of Apexigen Inc.
Apexigen Inc. operates as a biopharmaceutical product development company. It focuses on the development of product candidates for life-threatening and difficult to treat diseases. The company’s products include humanized antibodies for cancer, inflammatory diseases, and ophthalmic diseases. It discovers and develops rabbit-derived humanized monoclonal antibodies. The company was founded in 2010 and is based in Burlingame, California.
863 Mitten Road
Burlingame, CA 94010-1303
Founded in 2010
Key Executives for Apexigen Inc.
Apexigen Inc. Key Developments
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Bloomberg L.P.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Apexigen Inc., please visit www.apexigen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.